Xenetic Biosciences, Inc.XBIOEarnings & Financial Report
Nasdaq
XBIO Q3 2025 Key Financial Metrics
Revenue
$1.0M
Gross Profit
N/A
Operating Profit
$-544.7K
Net Profit
$-509.9K
Gross Margin
N/A
Operating Margin
-53.0%
Net Margin
-49.7%
YoY Growth
67.2%
EPS
$-0.33
Financial Flow
Xenetic Biosciences, Inc. Q3 2025 Financial Summary
Xenetic Biosciences, Inc. reported revenue of $1.0M for Q3 2025, with a net profit of $-509.9K (-49.7% margin). Cost of goods sold was N/A, operating expenses totaled N/A.
Key Financial Metrics
| Total Revenue | $1.0M |
|---|---|
| Net Profit | $-509.9K |
| Gross Margin | N/A |
| Operating Margin | -53.0% |
| Report Period | Q3 2025 |
Xenetic Biosciences, Inc. Annual Revenue by Year
Xenetic Biosciences, Inc. annual revenue history includes year-by-year totals (for example, 2024 revenue was $2.5M).
| Year | Annual Revenue |
|---|---|
| 2024 | $2.5M |
| 2023 | $2.5M |
| 2022 | $1.7M |
Income Statement
| Q4 2023 | Q1 2024 | Q2 2024 | Q3 2024 | Q4 2024 | Q1 2025 | Q2 2025 | Q3 2025 | |
|---|---|---|---|---|---|---|---|---|
| Revenue | $671963 | $510817 | $726404 | $614243 | $648820 | $593261 | $589897 | $1.0M |
| YoY Growth | 38.0% | -15.7% | 11.6% | 0.5% | -3.4% | 16.1% | -18.8% | 67.2% |
Balance Sheet
| Q4 2023 | Q1 2024 | Q2 2024 | Q3 2024 | Q4 2024 | Q1 2025 | Q2 2025 | Q3 2025 | |
|---|---|---|---|---|---|---|---|---|
| Assets | $10.6M | $9.4M | $9.0M | $8.0M | $6.9M | $5.8M | $5.4M | $5.1M |
| Liabilities | $809585 | $716494 | $1.6M | $1.0M | $894263 | $667927 | $903430 | $1.1M |
| Equity | $9.8M | $8.7M | $7.4M | $7.0M | $6.0M | $5.1M | $4.5M | $4.0M |
Cash Flow
| Q4 2023 | Q1 2024 | Q2 2024 | Q3 2024 | Q4 2024 | Q1 2025 | Q2 2025 | Q3 2025 | |
|---|---|---|---|---|---|---|---|---|
| Operating CF | $-793027 | $-1.2M | $-525104 | $-459037 | $-673992 | $-1.0M | $-383830 | $-658247 |